The recent acquisition of Mopec Group by Waud Capital Partners signals an exciting new chapter in healthcare equipment manufacturing. The transaction, which closed in January 2025, demonstrates how private equity leader Reeve Waud continues to identify and invest in companies poised for significant growth in the healthcare sector.
Mopec Group, which specializes in pathology and laboratory equipment, represents a strategic addition to Waud Capital’s healthcare portfolio. The company has built a strong reputation since its founding in 1992, providing essential equipment to hospitals, universities, and research facilities. Under the new ownership, Mopec is positioned to expand its market presence through both organic growth and strategic acquisitions.
The appointment of Brad Staley as Executive Chairman exemplifies the investment approach that has defined Reeve Waud’s success in private equity. Staley brings more than 25 years of healthcare and technology experience to the role, with particular expertise in specialty distribution and services sectors. This pairing of experienced leadership with promising companies has been a cornerstone of Waud Capital’s growth strategy.
The growth strategy for Mopec Group includes several key components that align with Waud Capital’s proven approach to value creation. First, the firm plans to invest in expanding Mopec’s product development capabilities, enabling the company to introduce new solutions that address evolving market needs. Second, there will be a focus on enhancing operational efficiency through technology and process improvements. Finally, the strategy includes identifying and pursuing strategic acquisitions that complement Mopec’s existing offerings.
This comprehensive approach to growth reflects the evolution of Waud Capital’s investment strategy under Reeve Waud’s leadership. The firm has developed sophisticated capabilities in areas such as market analysis, operational improvement, and strategic planning, allowing it to support portfolio companies in multiple aspects of their development.
The Mopec acquisition also demonstrates Waud Capital’s commitment to investing in healthcare infrastructure. The company’s products play a crucial role in pathology and laboratory operations, supporting essential medical services and research activities. This focus on fundamental healthcare needs aligns with the firm’s long-term investment philosophy, which emphasizes backing companies that provide critical products and services.
Looking ahead, the partnership between Waud Capital and Mopec Group promises to yield significant advances in laboratory and pathology equipment technology. The combination of Mopec’s industry expertise with Waud Capital’s resources and strategic guidance creates a strong foundation for innovation and market expansion.
For Reeve Waud and Waud Capital Partners, the Mopec acquisition represents another step in their mission to build market-leading companies that drive progress in healthcare. Through careful planning, experienced leadership, and strategic investment, they aim to help Mopec Group reach new heights in serving the medical community’s equipment needs.